Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer

NCT02869282 | Withdrawn

• 1 other identifier: IB2011-CHEMOPROST
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical

  At baseline

• Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical

  At 6 months

Study Arms (1)

Prospective cohort

Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.

Other: Blood samples; Other: Urine samples

Interventions

Blood samples OTHER

Additional blood samples at baseline, 6, 12, 18 and 24 months.

Prospective cohort

Urine samples OTHER

Additional urine samples at baseline, 6, 12, 18 and 24 months.

Prospective cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with a localized or metastatic prostate adenocarcinoma

You may qualify if:

• Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant)
• Patients with a detectable PSA (Prostate-Specific Antigen)
• Patients who signed an informed consent
• Patients over 18 years
• Patients belonging to the social security scheme

You may not qualify if:

• Active Hepatitis B or C virus
• HIV positive
• Patients who have received prior chemotherapy
• Patients with a second neoplasia treated in the last 5 years

Sponsors & Collaborators

• Institut Bergonié: lead

Study Sites (1)

Institut Bergonié

Bordeaux, 33076, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Additional blood and urine samples (8 ml blood and 20 ml urine tubes)

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 28, 2016
• First Posted: August 16, 2016
• Study Start: June 1, 2011
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: September 17, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)